{"disease":{"id":"idiopathic-thrombocytopenic-purpura","name":"Idiopathic thrombocytopenic purpura","therapeutic_area":"","data":{},"enrichment_level":0,"last_enriched_at":null,"visit_count":0,"created_at":"2026-04-19T18:31:21.150Z","updated_at":"2026-04-19T18:39:44.960Z","meddra_pt":null,"meddra_code":null,"icd10_codes":null,"synonyms":[],"prevalence_global":null,"prevalence_us":null,"marketed_drug_count":15,"pipeline_drug_count":0,"trial_count":0},"drugs":{"marketed":[{"drug_id":"romiplostim","indication_name":"Chronic idiopathic thrombocytopenic purpura","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Nplate","generic_name":"ROMIPLOSTIM","company_name":"Amgen","drug_phase":"marketed","molecular_target":"Thrombopoietin receptor","drug_class":"Thrombopoietin Receptor Agonist [EPC]","quality_score":70,"revenue":"1524.0","mechanism":"Nplate works by binding to the thrombopoietin receptor to stimulate platelet production."},{"drug_id":"eltrombopag","indication_name":"Chronic idiopathic thrombocytopenic purpura","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Promacta","generic_name":"ELTROMBOPAG","company_name":"Novartis","drug_phase":"marketed","molecular_target":"Thrombopoietin receptor","drug_class":"Thrombopoietin Receptor Agonist","quality_score":80,"revenue":"569","mechanism":"Promacta works by binding to the thrombopoietin receptor, stimulating platelet production in the bone marrow."},{"drug_id":"hydrocortisone-succinate","indication_name":"Idiopathic thrombocytopenic purpura","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Solu-Cortef","generic_name":"hydrocortisone succinate","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Glucocorticoid receptor","drug_class":"Corticosteroid","quality_score":42,"revenue":null,"mechanism":""},{"drug_id":"azathioprine","indication_name":"Refractory idiopathic thrombocytopenic purpura","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Imuran","generic_name":"AZATHIOPRINE","company_name":"Legacy Pharma","drug_phase":"marketed","molecular_target":"ATP-binding cassette sub-family G member 2","drug_class":"Purine Antimetabolite [EPC]","quality_score":55,"revenue":null,"mechanism":""},{"drug_id":"hydrocortisone-acetate","indication_name":"Idiopathic thrombocytopenic purpura","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Cortifoam","generic_name":"HYDROCORTISONE ACETATE","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Corticosteroid-binding globulin","drug_class":"Corticosteroid","quality_score":42,"revenue":null,"mechanism":""},{"drug_id":"cortisone-acetate","indication_name":"Idiopathic thrombocytopenic purpura","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Cortone","generic_name":"CORTISONE ACETATE","company_name":"","drug_phase":"marketed","molecular_target":"Corticosteroid-binding globulin","drug_class":"alpha-Adrenergic Agonist [EPC]","quality_score":29,"revenue":null,"mechanism":""},{"drug_id":"betamethasone-acetate","indication_name":"Idiopathic thrombocytopenic purpura","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Celestone Soluspan","generic_name":"BETAMETHASONE ACETATE","company_name":"","drug_phase":"marketed","molecular_target":"Glucocorticoid receptor","drug_class":"Corticosteroid","quality_score":42,"revenue":null,"mechanism":""},{"drug_id":"dexamethasone","indication_name":"Idiopathic thrombocytopenic purpura","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Decadron","generic_name":"dexamethasone","company_name":"Generic (originally Merck)","drug_phase":"marketed","molecular_target":"Annexin A1, Interleukin-4, Androgen receptor","drug_class":"Corticosteroid [EPC]","quality_score":44,"revenue":null,"mechanism":""},{"drug_id":"prednison","indication_name":"Idiopathic thrombocytopenic purpura","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"prednison","company_name":"Wen Zhang","drug_phase":"marketed","molecular_target":"Annexin A1, Sodium/nucleoside cotransporter 1, Glucocorticoid receptor","drug_class":"","quality_score":19,"revenue":null,"mechanism":null},{"drug_id":"methylprednisolone","indication_name":"Idiopathic thrombocytopenic purpura","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Medrol","generic_name":"methylprednisolone","company_name":"Generic (originally Upjohn/Pfizer)","drug_phase":"marketed","molecular_target":"Annexin A1, Short transient receptor potential channel 5, Glucocorticoid receptor","drug_class":"Glucocorticoid (corticosteroid)","quality_score":62,"revenue":null,"mechanism":"Potent synthetic glucocorticoid with 5x hydrocortisone potency and minimal mineralocorticoid activity, used for severe inflammatory conditions."},{"drug_id":"hydrocortisone","indication_name":"Idiopathic thrombocytopenic purpura","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Cortef","generic_name":"hydrocortisone","company_name":"Generic (originally Merck/Upjohn)","drug_phase":"marketed","molecular_target":"Annexin A1, Corticosteroid-binding globulin, Nitric oxide synthase, inducible","drug_class":"Corticosteroid [EPC]","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"triamcinolone","indication_name":"Idiopathic thrombocytopenic purpura","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Rodinolone","generic_name":"TRIAMCINOLONE","company_name":"","drug_phase":"marketed","molecular_target":"Glucocorticoid receptor","drug_class":"Corticosteroid","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"prednisone","indication_name":"Idiopathic thrombocytopenic purpura","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Deltasone","generic_name":"prednisone","company_name":"Generic (originally Schering)","drug_phase":"marketed","molecular_target":"Annexin A1, Sodium/nucleoside cotransporter 1, Glucocorticoid receptor","drug_class":"Corticosteroid [EPC]","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"fostamatinib","indication_name":"Chronic idiopathic thrombocytopenic purpura","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Tavalisse","generic_name":"FOSTAMATINIB","company_name":"Rigel Pharms","drug_phase":"marketed","molecular_target":"Receptor-type tyrosine-protein kinase FLT3","drug_class":"","quality_score":65,"revenue":null,"mechanism":"Tavalisse works by blocking the activity of the FLT3 enzyme, which is involved in the production of platelets."},{"drug_id":"betamethasone","indication_name":"Idiopathic thrombocytopenic purpura","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Betametasone","generic_name":"BETAMETHASONE","company_name":"","drug_phase":"marketed","molecular_target":"Glucocorticoid receptor","drug_class":"Corticosteroid","quality_score":65,"revenue":null,"mechanism":"Betamethasone works by binding to the glucocorticoid receptor, which then triggers a series of downstream effects that reduce inflammation and suppress the immune system."},{"drug_id":"cortisol","indication_name":"Idiopathic thrombocytopenic purpura","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Cortisol","company_name":"University of Zurich","drug_phase":"marketed","molecular_target":"Annexin A1, Corticosteroid-binding globulin, Nitric oxide synthase, inducible","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"prednisolone","indication_name":"Idiopathic thrombocytopenic purpura","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Prelone","generic_name":"prednisolone","company_name":"Generic (originally Schering)","drug_phase":"marketed","molecular_target":"Annexin A1, Corticosteroid-binding globulin, G-protein coupled bile acid receptor 1","drug_class":"Glucocorticoid (corticosteroid)","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"prednisolon","indication_name":"Idiopathic thrombocytopenic purpura","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"prednisolon","company_name":"Hannover Medical School","drug_phase":"marketed","molecular_target":"Annexin A1, Corticosteroid-binding globulin, G-protein coupled bile acid receptor 1","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"methylprednisolon","indication_name":"Idiopathic thrombocytopenic purpura","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Methylprednisolon","company_name":"Leiden University Medical Center","drug_phase":"marketed","molecular_target":"Annexin A1, Short transient receptor potential channel 5, Glucocorticoid receptor","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"prednisone","indication_name":"Idiopathic thrombocytopenic purpura in adults","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Deltasone","generic_name":"prednisone","company_name":"Generic (originally Schering)","drug_phase":"marketed","molecular_target":"Annexin A1, Sodium/nucleoside cotransporter 1, Glucocorticoid receptor","drug_class":"Corticosteroid [EPC]","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"nplate","indication_name":"Chronic idiopathic thrombocytopenic purpura","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Nplate","company_name":"Nantes University Hospital","drug_phase":"marketed","molecular_target":"Thrombopoietin receptor","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"dexamethasone-phosphate","indication_name":"Idiopathic thrombocytopenic purpura in adults","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Dexamethasone Sodium Phosphate","generic_name":"dexamethasone phosphate","company_name":"Merck & Co.","drug_phase":"marketed","molecular_target":"Androgen receptor, Glucocorticoid receptor, Mineralocorticoid receptor","drug_class":"Corticosteroid","quality_score":10,"revenue":null,"mechanism":""}],"pipeline":[],"offLabel":[],"totalMarketed":22,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT03219723","title":"Drug Use Surveillance of Takecab for \"Supplement to Helicobacter Pylori Eradication\"","phase":"","overall_status":"COMPLETED","enrollment_count":560,"lead_sponsor_name":"Takeda","has_results":true},{"nct_id":"NCT04014413","title":"Safety and Efficacy of Fecal Microbiota Transplantation","phase":"NA","overall_status":"RECRUITING","enrollment_count":450,"lead_sponsor_name":"Chinese University of Hong Kong","has_results":false},{"nct_id":"NCT03222843","title":"Multicentre, Randomised Phase III Study of the Efficacy and Safety of Hetrombopag Olamine in Idiopathic Thrombocytopenic Purpura (ITP) Patient","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":424,"lead_sponsor_name":"Jiangsu HengRui Medicine Co., Ltd.","has_results":false},{"nct_id":"NCT00508820","title":"An Open Label Study of Romiplostim in Adult Thrombocytopenic Subjects With ITP","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":407,"lead_sponsor_name":"Amgen","has_results":true},{"nct_id":"NCT00415532","title":"Romiplostim (AMG 531) Versus Medical Standard of Care for Immune (Idiopathic) Thrombocytopenic Purpura","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":234,"lead_sponsor_name":"Amgen","has_results":true},{"nct_id":"NCT00907478","title":"Study on Bone Marrow Morphology in Adults Receiving Romiplostim for Treatment of Thrombocytopenia Associated With Immune Thrombocytopenia Purpura (ITP)","phase":"PHASE4","overall_status":"COMPLETED","enrollment_count":169,"lead_sponsor_name":"Amgen","has_results":true},{"nct_id":"NCT05492409","title":"Study of the Safety and Immunogenicity of Long-term GNR-069 Therapy in ITP Patients","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":160,"lead_sponsor_name":"AO GENERIUM","has_results":false},{"nct_id":"NCT05220878","title":"Comparative Study of Clinical Efficacy and Safety of GNR-069 and Nplate in Patients With ITP","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":160,"lead_sponsor_name":"AO GENERIUM","has_results":false},{"nct_id":"NCT04071496","title":"Diagnostic of Chronic Thrombocytopenia","phase":"","overall_status":"COMPLETED","enrollment_count":158,"lead_sponsor_name":"University Hospital, Bordeaux","has_results":false},{"nct_id":"NCT06757257","title":"Special Drug Use-results Survey for Long-term Use (Fostamatinib)","phase":"","overall_status":"RECRUITING","enrollment_count":149,"lead_sponsor_name":"Kissei Pharmaceutical Co., Ltd.","has_results":false},{"nct_id":"NCT01988506","title":"Induction of Regulatory t Cells by Low Dose il2 in Autoimmune and Inflammatory Diseases","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":81,"lead_sponsor_name":"Assistance Publique - Hôpitaux de Paris","has_results":false},{"nct_id":"NCT03864796","title":"Role of CD11a in Pathogenesis of Primary ITP and Effect of Immunosuppressive Therapy on Its Level","phase":"","overall_status":"COMPLETED","enrollment_count":80,"lead_sponsor_name":"Assiut University","has_results":false},{"nct_id":"NCT01143038","title":"Interventional Study in Adults With Immune Thrombocytopenia Purpura (ITP) Receiving Romiplostim","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":75,"lead_sponsor_name":"Amgen","has_results":true},{"nct_id":"NCT01071954","title":"A Study Evaluating the Safety and Efficacy of Long-term Dosing of Romiplostim in Thrombocytopenic Pediatric Patients With Immune (Idiopathic) Thrombocytopenia Purpura","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":66,"lead_sponsor_name":"Amgen","has_results":true},{"nct_id":"NCT00102323","title":"AMG 531 Treatment of Thrombocytopenic Subjects With Immune (Idiopathic) Thrombocytopenic Purpura (ITP) Refractory to Splenectomy","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":63,"lead_sponsor_name":"Amgen","has_results":false},{"nct_id":"NCT00102336","title":"AMG 531 Treatment of Thrombocytopenic Subjects With Immune (Idiopathic) Thrombocytopenic Purpura (ITP) Prior to Splenectomy","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":62,"lead_sponsor_name":"Amgen","has_results":false},{"nct_id":"NCT00111475","title":"Evaluating the Safety and Efficacy of Romiplostim (AMG 531) in Thrombocytopenic Subjects With Immune Thrombocytopenic Purpura (ITP)","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":45,"lead_sponsor_name":"Amgen","has_results":true},{"nct_id":"NCT03421392","title":"Study of Platelets Sialylation by Flow Cytometry for the Differential Diagnosis of ICT","phase":"","overall_status":"COMPLETED","enrollment_count":40,"lead_sponsor_name":"Nantes University Hospital","has_results":false},{"nct_id":"NCT03412188","title":"The Effect of Eltrombopag on the Expression of Platelet Collagen Receptor GPVI in Pediatric ITP.","phase":"NA","overall_status":"COMPLETED","enrollment_count":36,"lead_sponsor_name":"Nayera Hazaa Elsherif","has_results":false},{"nct_id":"NCT04132050","title":"A Clinical Study in Patients With Chronic Idiopathic Thrombocytopenic Purpura in R788","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":34,"lead_sponsor_name":"Kissei Pharmaceutical Co., Ltd.","has_results":true},{"nct_id":"NCT00603642","title":"P3 Study to Evaluate Efficacy and Safety of AMG 531 in Thrombocytopenic Japanese Subjects With Immune (Idiopathic) Thrombocytopenic Purpura","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":34,"lead_sponsor_name":"Amgen","has_results":true},{"nct_id":"NCT06287567","title":"Lusutrombopag in the Treatment of Immune Thrombocytopenia (ITP)","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":17,"lead_sponsor_name":"Institute of Hematology & Blood Diseases Hospital, China","has_results":false}],"total":22},"guidelines":[],"source":"Drug Landscape verified database"}